<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Maxcyte Inc — News on 6ix</title>
<link>https://6ix.com/company/maxcyte-inc</link>
<description>Latest news and press releases for Maxcyte Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/maxcyte-inc" rel="self" type="application/rss+xml" />
<item>
<title>MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern</description>
</item>
<item>
<title>MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform</description>
</item>
<item>
<title>MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the</description>
</item>
<item>
<title>MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform</description>
</item>
<item>
<title>MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-unveils-expert-dtxtm-a-96-well-electroporation-platform-to-accelerate-discovery</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-unveils-expert-dtxtm-a-96-well-electroporation-platform-to-accelerate-discovery</guid>
<pubDate>Tue, 24 Feb 2026 13:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines wit</description>
</item>
<item>
<title>MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-24-2026</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:</description>
</item>
<item>
<title>MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-preliminary-unaudited-fourth-130500569</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-preliminary-unaudited-fourth-130500569</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today provided a preliminary update on financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Fourth Quarter and Full Year 2025 Results Core revenue in the fourth quarter is expe</description>
</item>
<item>
<title>MaxCyte Announces Planned CFO Transition in 2026</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-planned-cfo-transition-210800425</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-planned-cfo-transition-210800425</guid>
<pubDate>Wed, 12 Nov 2025 21:08:00 GMT</pubDate>
<description>Company initiates search for successorROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026. Mr. Swirsky and the Company are working c</description>
</item>
<item>
<title>MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-third-quarter-2025-210500987</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-third-quarter-2025-210500987</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance. Third Quarter and Recent Highlights Core business revenue of $6.4 million in the third quarter of 2025.Strategic Platform Lic</description>
</item>
<item>
<title>MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-preliminary-third-quarter-130500444</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-preliminary-third-quarter-130500444</guid>
<pubDate>Wed, 05 Nov 2025 13:05:00 GMT</pubDate>
<description>MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its prelimi</description>
</item>
<item>
<title>MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-report-third-quarter-2025-120500505</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-report-third-quarter-2025-120500505</guid>
<pubDate>Wed, 08 Oct 2025 12:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the third quarter 2025 after the U.S. market close on Wednesday, November 5th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eas</description>
</item>
<item>
<title>MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-strategic-platform-license-120500041</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-strategic-platform-license-120500041</guid>
<pubDate>Mon, 06 Oct 2025 12:05:00 GMT</pubDate>
<description>MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapiesROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License (SPL) agreement with Moonlight Bio, a preclin</description>
</item>
<item>
<title>MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-operational-restructuring-reduce-203000809</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-operational-restructuring-reduce-203000809</guid>
<pubDate>Mon, 22 Sep 2025 20:30:00 GMT</pubDate>
<description>ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company’s global workforce, inclusive of employees engaged through em</description>
</item>
<item>
<title>MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-second-quarter-2025-200500774</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-second-quarter-2025-200500774</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights Core business revenue of $8.2 million in the second quarter of 2025, an increase of 8% over the</description>
</item>
<item>
<title>MaxCyte Signs Platform License Agreement with Adicet Bio</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-signs-platform-license-agreement-120500076</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-signs-platform-license-agreement-120500076</guid>
<pubDate>Mon, 04 Aug 2025 12:05:00 GMT</pubDate>
<description>MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, I</description>
</item>
<item>
<title>MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-strategic-platform-licensing-120500920</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-announces-strategic-platform-licensing-120500920</guid>
<pubDate>Thu, 31 Jul 2025 12:05:00 GMT</pubDate>
<description>MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leadin</description>
</item>
<item>
<title>MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-report-second-quarter-2025-120500588</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-report-second-quarter-2025-120500588</guid>
<pubDate>Wed, 09 Jul 2025 12:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. East</description>
</item>
<item>
<title>PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan</title>
<link>https://6ix.com/company/maxcyte-inc/news/phc-announces-exclusive-distribution-of-maxcyter-experttm-platform-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/phc-announces-exclusive-distribution-of-maxcyter-experttm-platform-in-japan</guid>
<pubDate>Tue, 01 Jul 2025 05:00:00 GMT</pubDate>
<description>TOKYO, July 01, 2025--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo, hereafter referred to as "PHCHD") announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform(*1) in Japan. In Singapore, SciMed (Asia) Pte Ltd, a subsidiary of PHCHD, separately entered into an exclusive distribut</description>
</item>
<item>
<title>MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-ori-biotech-collaborate-improve-060000903</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-ori-biotech-collaborate-improve-060000903</guid>
<pubDate>Wed, 11 Jun 2025 06:00:00 GMT</pubDate>
<description>MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelinesROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and</description>
</item>
<item>
<title>MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance</title>
<link>https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-first-quarter-2025-200500896</link>
<guid isPermaLink="true">https://6ix.com/company/maxcyte-inc/news/maxcyte-reports-first-quarter-2025-200500896</guid>
<pubDate>Wed, 07 May 2025 20:05:00 GMT</pubDate>
<description>ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights Core business revenue of $8.2 million in the first quarter of 2025, an increase of</description>
</item>
</channel>
</rss>